The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Open accessPublished version of a preprint
Abstract
Immune checkpoint inhibitors (ICIs) have obtained durable responses in many cancers, making it possible to foresee their potential in improving the health of cancer patients. However, immunotherapies are currently limited to a minority of patients and there is a need to develop a better understanding of the basic molecular mechanisms and functions of pivotal immune regulatory molecules. Immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and regulatory T (Treg) cells play pivotal roles in hindering the anticancer immunity. Treg cells suppress antigen-presenting cells (APCs) by depleting immune stimulating cytokines, producing immunosuppressive cytokines and constitutively expressing CTLA-4. CTLA-4 molecules bind to CD80 and CD86 with a higher affinity than CD28 and act as competitive inhibitors of CD28 in APCs. The purpose of this review is to summarize state-of-the-art understanding of the molecular mechanisms underlining CTLA-4 immune regulation and the correlation of the ICI response with CTLA-4 expression in Treg cells from preclinical and clinical studies for possibly improving CTLA-4-based immunotherapies, while highlighting the knowledge gap.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×
“This could be a reason why tumors with neoantigens respond better to immune checkpoint and tumors with low mutational burden are nonresponsive[108,109].”
BackgroundFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“In adult mice it was observed that conditional deletion of CTLA-4 resulted in hypergammaglobulinemia, spontaneous lymphoproliferation and histologically evident gastritis, organi-specific autoantibodies generation, insulitis, pneumonits and sialadenitis[128].”
BackgroundSakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citationThe Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., & Vignali, D. A. A. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,066
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 2×
“Another mechanism by which CTLA-4 can lower the total availability of CD80/86 ligands is through APC-mediated trans-endocytosis of CD80/86 ligands [36].”
BackgroundCytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 1×
“CTLA-4 competes against costimulatory molecule CD28 for the B7 ligand CD80 and CD86, for which it has higher affinity and avidity [17,18].”
BackgroundSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,568
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Foxp3+ follicular regulatory T cells control the germinal center response
Linterman, M. A., Pierson, W., Lee, S. K., Kallies, A., Kawamoto, S., Rayner, T. F., Srivastava, M., Divekar, D. P., Beaton, L., Hogan, J. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2425 · Cited by 1,292
Koch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
Induction of tolerance by IL-10-treated dendritic cells
Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,246
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232 · cited 1×
“T cells with γδ expression, representing the first layer of defense, constitute nearly 2% of the T cell population in peripheral blood and secondary lymphoid organs, while they are mainly found in the epithelia of the skin, gut, lung, and other organs [15,16].”
BackgroundCancer statistics for adolescents and young adults, 2020
Miller, K. D., Fidler‐Benaoudia, M., Keegan, T. H., Hipp, H. S., Jemal, A., & Siegel, R. L. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21637 · Cited by 1,190
Wei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions
Chung, Y., Tanaka, S., Chu, F., Nurieva, R. I., Martinez, G. J., Rawal, S., Wang, Y.-H., Lim, H., Reynolds, J. M., Zhou, X.-H., et al. (2011) · Nature Medicine · doi:10.1038/nm.2426 · Cited by 1,120
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107
Hori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,066
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
TOWARD AN UNDERSTANDING OF NKT CELL BIOLOGY: Progress and Paradoxes
Kronenberg, M. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115742 · Cited by 1,029
CD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000
The epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986
Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Ohkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y., Osaki, M., Tanaka, Y., Yamashita, R., Nakano, N., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.010 · Cited by 754
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750 · cited 1×
“Moreover, peptides have recommended themselves in a variety of therapeutic areas, including cancer [68,69].”
BackgroundMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · cited 3×
“Apoptotic Treg use the A2A pathway to suppress immune cells [7,84].”
BackgroundInfluentialInduction of Peripheral T Cell Tolerance In Vivo Requires CTLA-4 Engagement
Perez, V. L., Van Parijs, L., Biuckians, A., Zheng, X. X., Strom, T. B., & Abbas, A. K. (1997) · Immunity · doi:10.1016/s1074-7613(00)80284-8 · Cited by 716
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 3×
“observed that a CTLA-4 blockade with GM-CSF combination immunotherapy in an in vivo B16/BL6 mouse model of melanoma led to a self-expansion of Treg cells in tumors [47].”
BackgroundInfluentialImpact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
γδ T Cells: First Line of Defense and Beyond
Chien, Y.-H., Meyer, C., & Bonneville, M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120216 · Cited by 636
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.393 · Cited by 551 · cited 1×
“43 s-1)[20], which permits their instant competition.”
Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4
Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551
Egen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 535
Multiple roles for CD4+ T cells in anti‐tumor immune responses
Kennedy, R., & Celis, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00616.x · Cited by 511
A Kinetic Basis For T Cell Receptor Repertoire Selection during an Immune Response
Savage, P. A., Boniface, J. J., & Davis, M. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80048-5 · Cited by 497
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., Stahl, M. L., Seehra, J., Somers, W. S., & Mosyak, L. (2001) · Nature · doi:10.1038/35069118 · Cited by 489
Lanier, L. L., O'Fallon, S., Somoza, C., Phillips, J. H., Linsley, P. S., Okumura, K., Ito, D., & Azuma, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.97 · Cited by 480
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Jarnicki, A. G., Lysaght, J., Todryk, S., & Mills, K. H. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.896 · Cited by 445
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407 · cited 2×
“FAK kinase inhibitor VS-4718 drove Treg cells depletion and promoted the anti-tumor response of CD8+ T cells[105].”
BackgroundT Cell Affinity Maturation by Selective Expansion during Infection
Busch, D. H., & Pamer, E. G. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.4.701 · Cited by 406
Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling
Pagès, F., Ragueneau, M., Rottapel, R., Truneh, A., Nunes, J., Imbert, J., & Olive, D. (1994) · Nature · doi:10.1038/369327a0 · Cited by 398
The significance of exosomes in the development and treatment of hepatocellular carcinoma
Li, X., Li, C., Zhang, L., Wu, M., Cao, K., Jiang, F., Chen, D., Li, N., & Li, W. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1085-0 · Cited by 395
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
Schwartz, J.-C. D., Zhang, X., Fedorov, A. A., Nathenson, S. G., & Almo, S. C. (2001) · Nature · doi:10.1038/35069112 · Cited by 349
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines
Kane, L. P., Andres, P. G., Howland, K. C., Abbas, A. K., & Weiss, A. (2001) · Nature Immunology · doi:10.1038/83144 · Cited by 316
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Interleukin-35 Limits Anti-Tumor Immunity
Turnis, M. E., Sawant, D. V., Szymczak-Workman, A. L., Andrews, L. P., Delgoffe, G. M., Yano, H., Beres, A. J., Vogel, P., Workman, C. J., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.013 · Cited by 311
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Mucosal-associated invariant T cells and disease
Toubal, A., Nel, I., Lotersztajn, S., & Lehuen, A. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0191-y · Cited by 300
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Friedline, R. H., Brown, D. S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., Appleby, M., Der, S. D., Kang, J., & Chambers, C. A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081811 · Cited by 266
IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer
Kryczek, I., Wu, K., Zhao, E., Wei, S., Vatan, L., Szeliga, W., Huang, E., Greenson, J., Chang, A., Roliński, J., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003251 · Cited by 264
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256 · cited 1×
“The drug was administered every 28 days[127].”
Jain, N., Nguyen, H., Chambers, C., & Kang, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910341107 · Cited by 256
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 249
Cutting Edge: Lymphoproliferative Disease in the Absence of CTLA-4 Is Not T Cell Autonomous
Bachmann, M. F., Köhler, G., Ecabert, B., Mak, T. W., & Kopf, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1128 · Cited by 235
Tada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 214
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
Paterson, A. M., Lovitch, S. B., Sage, P. T., Juneja, V. R., Lee, Y., Trombley, J. D., Arancibia-Cárcamo, C. V., Sobel, R. A., Rudensky, A. Y., Kuchroo, V. K., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141030 · Cited by 212
Williams, J. B., Horton, B. L., Zheng, Y., Duan, Y., Powell, J. D., & Gajewski, T. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160485 · Cited by 210
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
Maeda, Y., Nishikawa, H., Sugiyama, D., Ha, D., Hamaguchi, M., Saito, T., Nishioka, M., Wing, J. B., Adeegbe, D., Katayama, I., et al. (2014) · Science · doi:10.1126/science.aaa1292 · Cited by 200
Vaccines targeting helper T cells for cancer immunotherapy
Melssen, M., & Slingluff, C. L. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.004 · Cited by 192
Fellner, C. (2012) · Europe PMC (PubMed Central) · Cited by 183
FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., Vatan, L., Finlayson, E., Huang, E., Simeone, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3804 · Cited by 179
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., Wong, S. C., Bell, A., Mankikar, S., Rangan, V. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617941114 · Cited by 162
Thymocyte development is normal in CTLA-4-deficient mice
Chambers, C. A., Cado, D., Truong, T. V., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9296 · Cited by 160
Wei, S., Kryczek, I., Edwards, R. P., Zou, L., Szeliga, W., Banerjee, M., Cost, M., Cheng, P., Chang, A., Redman, B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0565 · Cited by 159
Improved Method for the Identification and Validation of Allosteric Sites
Song, K., Liu, X., Huang, W., Lu, S., Shen, Q., Zhang, L., & Zhang, J. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00014 · Cited by 158
Ji, D., Song, C., Li, Y., Xia, J., Wu, Y., Jia, J., Cui, X., Yu, S., & Gu, J. F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000826 · Cited by 158
Self-citationAtkins, M. B., Clark, J. I., & Quinn, D. I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx151 · Cited by 156
The reverse stop-signal model for CTLA4 function
Rudd, C. E. (2008) · Nature reviews. Immunology · doi:10.1038/nri2253 · Cited by 155
Regulatory T Cells Increase the Avidity of Primary CD8 + T Cell Responses and Promote Memory
Pace, L., Tempez, A., Arnold-Schrauf, C., Lemaitre, F., Bousso, P., Fetler, L., Sparwasser, T., & Amigorena, S. (2012) · Science · doi:10.1126/science.1227049 · Cited by 152
Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE
Van Kaer, L., Postoak, J. L., Wang, C., Yang, G., & Wu, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0221-5 · Cited by 148
Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28
Metzler, W. J., Bajorath, J., Fenderson, W., Shaw, S., Constantine, K. L., Naemura, J. R., Leytze, G., Peach, R., Lavoie, T., Mueller, L., et al. (1997) · Nature Structural Biology · doi:10.1038/nsb0797-527 · Cited by 147
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Pai, C.-C. S., Simons, D. M., Lu, X., Evans, M. J., Wei, J., Wang, Y.-H., Chen, M., Huang, J., Park, C., Chang, A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123391 · Cited by 147
Mougiakakos, D., Johansson, C. C., Trocmé, E., All‐Ericsson, C., Economou, M. A., Larsson, O., Seregard, S., & Kiessling, R. W. (2010) · Cancer · doi:10.1002/cncr.24999 · Cited by 146
TNFR2: A Novel Target for Cancer Immunotherapy
Vanamee, É. S., & Faustman, D. L. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.09.007 · Cited by 146
Morikawa, H., Ohkura, N., Vandenbon, A., Itoh, M., Nagao-Sato, S., Kawaji, H., Lassmann, T., Carninci, P., Hayashizaki, Y., Forrest, A. R. R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312717110 · Cited by 141
Hindley, J. P., Ferreira, C., Jones, E., Lauder, S. N., Ladell, K., Wynn, K. K., Betts, G. J., Singh, Y., Price, D. A., Godkin, A. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1797 · Cited by 140
Treg Depletion Licenses T Cell–Driven HEV Neogenesis and Promotes Tumor Destruction
Colbeck, E. J., Jones, E., Hindley, J. P., Smart, K., Schulz, R., Browne, M., Cutting, S., Williams, A. S., Parry, L., Godkin, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0131 · Cited by 138
Regulatory T cells in health and disease
Piccirillo, C. A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.469 · Cited by 133
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
Nishikawa, H., Kato, T., Tawara, I., Saito, K., Ikeda, H., Kuribayashi, K., Allen, P. M., Schreiber, R. D., Sakaguchi, S., Old, L. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041959 · Cited by 130
Hindley, J. P., Jones, E., Smart, K., Bridgeman, H. M., Lauder, S. N., Ondondo, B., Cutting, S., Ladell, K., Wynn, K. K., Withers, D. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1912 · Cited by 129
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.986 · Cited by 128
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
Wang, H., Sun, Y., Zhou, X., Chen, C., Jiao, L., Li, W., Gou, S., Li, Y., Du, J., Chen, G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000905 · Cited by 127
Self-citationKvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0570-8 · Cited by 126
Hoelzinger, D. B., Smith, S. E., Mirza, N. N., Dominguez, A. L., Manrique, S. Z., & Lustgarten, J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904084 · Cited by 123
Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment
Xie, J., Si, X., Gu, S., Wang, M., Shen, J. H., Li, H., Shen, J. H., Li, D., Fang, Y., Liu, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01520 · Cited by 117
Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
Tang, F., Du, X., Liu, M., Zheng, P., & Liu, Y. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0229-z · Cited by 114
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
Corse, E., & Allison, J. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200695 · Cited by 111
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
He, M., Chai, Y., Qi, J., Zhang, C. W. H., Tong, Z., Shi, Y., Yan, J., Tan, S., & Gao, G. F. (2017) · Oncotarget · doi:10.18632/oncotarget.18004 · Cited by 106
Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102
CTLA-4 expression by B-1a B cells is essential for immune tolerance
Yang, Y., Li, X., Ma, Z., Wang, C., Yang, Q., Byrne-Steele, M. L., Hong, R., Min, Q., Zhou, G., Cheng, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20874-x · Cited by 102
γδ T cells in cancer: a small population of lymphocytes with big implications
Raverdeau, M., Cunningham, S., Harmon, C., & Lynch, L. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1080 · Cited by 98
CTLA‐4, a Negative Regulator of T‐Lymphocyte Activation
Waterhouse, P. D., Marengère, L. E. M., Mittrücker, H., & Mak, T. W. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00925.x · Cited by 94
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A., Tötterman, T. H., & Mangsbo, S. M. (2014) · OncoImmunology · doi:10.4161/onci.27614 · Cited by 88
MAIT cells and MR1-antigen recognition
Keller, A. N., Corbett, A. J., Wubben, J. M., McCluskey, J., & Rossjohn, J. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.002 · Cited by 87
Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation
Togashi, Y., & Nishikawa, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_58 · Cited by 86
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
Zhang, F., Qi, X., Wang, X., Wei, D., Wu, J., Feng, L., Cai, H., Wang, Y., Zeng, N., Xu, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21652 · Cited by 86
Sainz‐Perez, A., Lim, A., Lemercier, B., & Leclerc, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0277 · Cited by 83
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites
Morris, Z. S., Guy, E. I., Werner, L. R., Carlson, P. M., Heinze, C. M., Kler, J. S., Busche, S. M., Jaquish, A. A., Sriramaneni, R. N., Carmichael, L. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0353 · Cited by 75
Khan, S. S., Burt, D. J., Ralph, C., Thistlethwaite, F. C., Hawkins, R. E., & Elkord, E. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.09.011 · Cited by 73
Unraveling Natural Killer T-Cells Development
Bennstein, S. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01950 · Cited by 67
Parallels and differences between innate and adaptive lymphocytes
Bedoui, S., Gebhardt, T., Gasteiger, G., & Kastenmüller, W. (2016) · Nature Immunology · doi:10.1038/ni.3432 · Cited by 62
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.993 · Cited by 57
Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
Yu, C., Sonnen, A. F. ‐., George, R., Dessailly, B. H., Stagg, L., Evans, E. J., Orengo, C. A., Stuart, D. I., Ladbury, J. E., Ikemizu, S., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182394 · Cited by 56
Roca, C., Requena-Triguero, C., Sebastián-Pérez, V., Malhotra, S., Radoux, C. J., Pérez, C., Martı́nez, A., Paez, J. A., Blundell, T. L., & Campillo, N. E. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1476502 · Cited by 54
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Duperret, E. K., Wise, M. C., Trautz, A., Villarreal, D. O., Ferraro, B., Walters, J. N., Yan, J., Khan, A. S., Masteller, E. L., Humeau, L. M. P. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.010 · Cited by 45
MAIT cells: an historical and evolutionary perspective
Lantz, O. J., & Legoux, F. P. (2017) · Immunology and Cell Biology · doi:10.1111/imcb.1034 · Cited by 43
Foell, J., Hewes, B., & Mittler, R. S. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006841 · Cited by 35
Schwarz, C. C., Unger, L. W., Mahr, B., Aumayr, K., Regele, H. M., Farkas, A. M., Hock, K., Pilat, N., & Wekerle, T. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13872 · Cited by 34
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
Qu, Q., Zhai, Z., Xu, J., Li, S., Chen, C., & Lu, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00634 · Cited by 31
The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events
Mihic‐Probst, D., Reinehr, M. D., Dettwiler, S., Kolm, I., Britschgi, C., Kudura, K., Maggio, E. M., Lenggenhager, D. M., & Rushing, E. J. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152009 · Cited by 29
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Zeng, G., Jin, L., Ying, Q., Chen, H., Thembinkosi, M. C., Yang, C., Zhao, J., Ji, H., Lin, S., Peng, R., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s265828 · Cited by 28
Oncogenes in immune cells as potential therapeutic targets
Zakiryanova, G. K., Wheeler, S., & Shurin, M. R. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s150586 · Cited by 21
New insights on T-cell self-tolerance
Yi, J., Kawabe, T., & Sprent, J. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.10.002 · Cited by 21
Sun, N.-Y., Chen, Y., Lin, H.-W., Chiang, Y., Chang, C.-F., Tai, Y., Chen, C., Sun, W., Chien, C. L., & Cheng, W. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.039 · Cited by 18
Son, C., Bae, J., Lee, H.-R., Yang, K., & Park, Y.-S. (2017) · Oncology Letters · doi:10.3892/ol.2017.5933 · Cited by 14
Suppression from beyond the grave
Togashi, Y., & Nishikawa, H. (2017) · Nature Immunology · doi:10.1038/ni.3870 · Cited by 11
CTLA‐4 lacking the cytoplasmic domain costimulates IL‐2 production in T‐cell hybridomas
Hueber, A. J., Matzkies, F. G., Rahmeh, M., Manger, B., Kalden, J. R., & Nagel, T. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01402.x · Cited by 10
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Self-citationImmunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Metadata
- Authors
- Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-03-22
- Volume
- 13
- Issue
- 6
- Pages
- 1440
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3127895014
- Cited by
- 303
- References
- 163
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.